Meeting
2014 ASCO Annual Meeting
SOLO1 and SOLO2: Randomized phase III trials of olaparib in patients (pts) with ovarian cancer and a BRCA1/2 mutation (BRCAm).
Authors
Kathleen N. Moore
University of Oklahoma Health Sciences Center, Oklahoma City, OK
Kathleen N. Moore , Paul DiSilvestro , Elizabeth S. Lowe , Sally Garnett , Eric Pujade-Lauraine
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01844986 and NCT01874353
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS5616)
DOI
10.1200/jco.2014.32.15_suppl.tps5616
Abstract #
TPS5616
Poster Bd #
395B
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Locus-specific loss of heterozygosity (LOH) in BRCA1/2 mutated (mBRCA) ovarian tumors from the SOLO2 (NCT01874353) and Study 19 (NCT00753545) clinical trials.
First Author: Kirsten Timms
Poster
2014 ASCO Annual Meeting
Analysis of candidate homologous repair deficiency genes in a clinical trial of olaparib in patients (pts) with platinum-sensitive, relapsed serous ovarian cancer (PSR SOC).
First Author: Brian Dougherty
Poster
2016 ASCO Annual Meeting
SOLO3: A randomized phase III trial of olaparib versus chemotherapy in platinum-sensitive relapsed ovarian cancer patients with a germline BRCA1/2 mutation (gBRCAm).
First Author: Elizabeth S. Lowe
Poster
2021 ASCO Annual Meeting
KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.
First Author: Andreas Rimner